Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial

Lipids in Health and Disease
Richard L DunbarMichael H Davidson

Abstract

This study examined the effects of a mixture of highly bioavailable omega-3 carboxylic acids (OM3-CA) on nuclear magnetic resonance spectroscopy-assessed lipoprotein particle concentrations and sizes and other cardiovascular risk markers in statin-treated patients with fasting triglycerides (TG) ≥ 2.3 mmol/L (200 mg/dL) and <5.6 mmol/L (500 mg/dL) and at high cardiovascular risk. After a diet lead-in and statin-stabilization period, 647 patients were randomly assigned to receive capsules of control (olive oil, OO) 4 g/d, OM3-CA 2 g/d (plus OO 2 g/d), or OM3-CA 4 g/d for 6 weeks. Compared with OO, low-density lipoprotein (LDL) particle size was increased with OM3-CA 2 g/d (p < 0.01) and 4 g/d (p < 0.001), and very low-density lipoprotein (VLDL) and high-density lipoprotein (HDL) particle sizes were decreased with both OM3-CA dosages vs. OO (p < 0.001 and p < 0.05 for VLDL and HDL, respectively). Total VLDL/chylomicron remnant particle concentration was reduced by 8.5 and 16.0 % with OM3-CA 2 and 4 g/d, respectively, vs. a 6.9 % reduction with OO (p < 0.001 for OM3-CA 4 g/d vs. OO). Total HDL particle concentration was also reduced by 1.5 and 3.2 % with OM3-CA 2 and 4 g/d, respectively, vs. a 0.6 % increase with OO (at least p < ...Continue Reading

References

Dec 29, 1998·Journal of Cardiovascular Risk·W S HarrisK Osmundsen
Feb 4, 2003·Journal of Lipid Research·Yongsoon Park, William S Harris
Jul 16, 2003·The American Journal of Cardiology·Peter H JonesUNKNOWN STELLAR Study Group
Aug 13, 2003·Current Atherosclerosis Reports·Paul M RidkerPeter P Toth
Jun 27, 2006·Clinical Cardiology·Michael H DavidsonUNKNOWN TRIMS Investigators
Jul 13, 2006·Current Opinion in Lipidology·William S Harris, Deepti Bulchandani
Aug 22, 2006·The American Journal of Cardiology·Michael H Davidson
Dec 28, 2007·Atherosclerosis·William S HarrisErnst J Schaefer
Apr 30, 2008·Clinical Science· Yasmin, Kevin M O'Shaughnessy
Mar 6, 2009·Journal of Atherosclerosis and Thrombosis·Akio Kawakami, Masayuki Yoshida
Jul 4, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Tomoyuki NishimotoDaniel J Rader
Mar 13, 2010·Expert Review of Cardiovascular Therapy·Peter P TothKenneth J Colley
Jun 1, 2009·Current Opinion in Lipidology·Janet D Sparks, Henry H Dong
Jan 14, 2011·The New England Journal of Medicine·Amit V KheraDaniel J Rader
Feb 18, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Henry N Ginsberg, W Virgil Brown
Mar 27, 2012·The Journal of Nutritional Biochemistry·Yu-Jen ChenShih-Torng Ding
Sep 18, 2012·Lipids in Health and Disease·Elena BurilloFernando Civeira
Mar 8, 2013·Future Cardiology·Yu KataokaStephen J Nicholls
Jul 17, 2013·International Journal of Cardiology·Angela Pirillo, Alberico Luigi Catapano
Apr 1, 2014·The New England Journal of Medicine·Harvey D WhiteLars Wallentin
Jun 19, 2014·The New England Journal of Medicine·Jacy CrosbySekar Kathiresan
Jun 19, 2014·The New England Journal of Medicine·Anders Berg JørgensenAnne Tybjærg-Hansen
Sep 1, 2014·JAMA : the Journal of the American Medical Association·Michelle L O'DonoghueDylan L Steen

❮ Previous
Next ❯

Citations

Aug 14, 2019·European Journal of Preventive Cardiology·Katharina LechnerJohannes Scherr
Nov 23, 2019·Expert Opinion on Investigational Drugs·David RhaindsJean-Claude Tardif
Aug 20, 2019·Circulation·Ann C Skulas-RayUNKNOWN American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometa
Oct 7, 2016·Postgraduate Medicine·Pamela A Kushner, Michael E Cobble
Aug 26, 2015·Cardiovascular Diabetology·Yuri Karpov, Yunona Khomitskaya
Apr 12, 2016·Drugs & Therapy Perspectives : for Rational Drug Selection and Use·Richard S Castaldo
Nov 3, 2016·Current Opinion in Lipidology·Michael H Davidson, Lane B Benes
May 22, 2019·Current Atherosclerosis Reports·Marja-Riitta TaskinenJan Borén
Dec 20, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Kohei Takata, Stephen J Nicholls
Mar 28, 2020·Arteriosclerosis, Thrombosis, and Vascular Biology·R Preston MasonDeepak L Bhatt
Nov 8, 2016·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Yehuda Handelsman, Michael D Shapiro
Aug 28, 2020·Frontiers in Endocrinology·Jan BorénMarja-Riitta Taskinen
Oct 17, 2020·European Heart Journal Supplements : Journal of the European Society of Cardiology·Timothy D O'ConnellGregory C Shearer
May 3, 2021·Clinical Nutrition : Official Journal of the European Society of Parenteral and Enteral Nutrition·Elise GryttenOttar K Nygård
Aug 29, 2021·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Katharina LechnerFrank Edelmann

❮ Previous
Next ❯

Methods Mentioned

BETA
Nuclear

Clinical Trials Mentioned

NCT02104817

Software Mentioned

Epanova
ESPRIT
SAS

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.